Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.63 |
| ▸ | ALPI | P09923 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | XIAP | P98170 | 1/20 | 0.63 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | ANPEP | P15144 | 2/20 | 0.46 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7111513 | 1.00 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL5479690 | 0.98 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL5479695 | 0.98 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL28597069 | 0.86 | SLC7A5 (0.76) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL30636861 | 0.81 | ALPI (0.50) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28067572 | 0.81 | SLC7A5 (0.88) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL13118180 | 0.81 | SLC7A5 (0.68) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL1436733 | 0.81 | SLC7A5 (0.58) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL1436736 | 0.81 | SLC7A5 (0.58) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL5479700 | 0.80 | SLC7A5 (0.56) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014201111-A1 | TREATMENT OF MTOR HYPERACTIVE RELATED DISEASES AND DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| EP-2295082-B1 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | FDS PHARMA ASS (GB) | 2013-09-18 | — | — | EP | disclosed |
| EP-1394261-B1 | ANTIGENS FOR IMMUNISATION | FDS PHARMA ASS (GB) | 2011-03-30 | — | — | EP | disclosed |
| EP-2295082-A1 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | FDS Pharma Ass. (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-7560229-B2 | Methods of use of the enzymes of mycothiol synthesis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560529-B2 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | FDS Pharma (GB) | 2009-07-14 | — | — | US | disclosed |
| WO-2008078177-A2 | METHOD FOR PRODUCING CATALYTIC ANTIBODIES (VARIANTS), ANTIGENS FOR IMMUNIZATION AND NUCLEOTIDE SEQUENCE | FDS PHARMA ASS. (RU) | 2008-07-03 | — | — | WO | disclosed |
| US-20070178109-A1 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | LIFEBIO LABORATORIES LLC | 2007-08-02 | — | — | US | disclosed |
| US-20060183116-A1 | Methods of use of the enzymes of mycothiol synthesis | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2006-08-17 | — | — | US | disclosed |
| EP-1601764-A2 | A CLASS OF METACASPASES | VIB vzw (BE) | 2005-12-07 | — | — | EP | disclosed |
| US-20040265975-A1 | glycoprotein 120; fusion proteins; myelin basic protein; autoimmune diseases; genetic vaccines | FDS PHARMA ASS. (GB) | 2004-12-30 | — | — | US | disclosed |
| WO-2004081168-A2 | A CLASS OF METACASPASES | VIB VZW (BE) | 2004-09-23 | — | — | WO | disclosed |
| EP-1394261-A2 | METHOD FOR PRODUCING CATALYTIC ANTIBODIES (VARIANTS), ANTIGENS FOR IMMUNISATION AND NUCLEOTIDE SEQUENCE | ASGL - Farmatsevticjeskie Innovatsii, Zaptryote Aktsionernoe Obschestvo (RU) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003089585-A2 | METHODS OF USE OF THE ENZYMES OF MYCOTHIOL SYNTHESIS | THE REGENTS OF THE UNIVERISTY OF CALIFORNIA (US) | 2003-10-30 | — | — | WO | disclosed |
| US-6242448-B1 | Trisubstituted-oxazole derivatives as serotonin ligands | AMERICAN HOME PRODUCTS CORPORATION | 2001-06-05 | — | — | US | disclosed |
| EP-1053235-A1 | OXAZOLE DERIVATIVES AS SEROTONIN-1A RECEPTOR AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-22 | — | — | EP | disclosed |
| US-6057340-A | Oxazole derivatives as serotonin-1A receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1999038864-A1 | OXAZOLE DERIVATIVES AS SEROTONIN-1A RECEPTOR AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070178109-A1 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | SSB, DNMT3L, NASP | SLC7A5 4534/4885ALPI 1231/4885PKM 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.